Outcomes of relapsed/refractory patients with AML treated with TVTC. (A) Five-year OS of patients in Group A vs Group B. (B) Five-year OS according to response to TVTC. (C) Five-year OS of responders who proceeded to allogeneic HSCT (n = 16).